A search for “7oh ban” can produce two apparently incompatible answers: an announcement says federal authorities intend to control certain 7-hydroxymitragynine products, while another source says the order has not yet been issued. The difference matters. A notice of intent is a step toward an order; the date on which an order may be published is not itself an order. The contents of the package, the date of the conduct, and the particular federal or state rule also matter.
As of November 14, 2026, the Drug Enforcement Administration’s October notice described a future federal temporary scheduling order for 7-hydroxymitragynine, commonly called 7-OH, and mitragynine pseudoindoxyl above specified thresholds. The notice said the order would be published on or after November 13. A Federal Register search for documents on 7-hydroxymitragynine published since October 14 returned the notice and a withdrawal, but no later order in those search results. A separate August order had already placed mitragynine pseudoindoxyl and two other named substances in Schedule I. The October notice stated that this existing order remained in effect unless it expired or was replaced and withdrawn.
For a consumer, retailer, or person facing an investigation, the useful first question is therefore not simply whether an internet headline says “banned.” Identify the exact substance, save the package and any test information, and check the federal document effective on the relevant date. Federal analogue rules and state laws present separate questions; neither can be resolved from a product name alone.
I. What does the federal 7-OH notice actually change?
A. Which federal documents should you check first?
Start with the October 14, 2026 Federal Register notice. The DEA called it a proposed amendment and notice of intent. It described the agency’s plan to issue a temporary order under the federal Controlled Substances Act; it did not itself say the proposed threshold had already become the final scheduling rule. The notice said the order would be published on or after November 13, 2026. That wording identifies the earliest publication point, not an automatic switch triggered by the calendar.
The federal notice describes 7-OH and mitragynine pseudoindoxyl together, but their existing legal positions cannot simply be merged. The DEA stated that its August 26, 2026 temporary order placed mitragynine pseudoindoxyl, MGM-15, and MGM-16 in Schedule I. The October notice said that the earlier order for mitragynine pseudoindoxyl remained in effect until it expired or a new temporary order was published and the earlier order withdrawn, whichever came first. The proposed new threshold for 7-OH is not a reason to disregard the existing order for a different named substance.
As another federal check, the electronic Code of Federal Regulations, 21 C.F.R. § 1308.11, displays the Schedule I entries. The edition consulted for this article states that Title 21 was current through November 12, 2026. An electronic compilation can lag a newly published order, so compare it with later Federal Register documents and their effective-date language. A lack of a later entry in that particular edition does not establish the status of an order published after its stated currency date.
Federal law supplies a procedure for temporary scheduling. The Office of the Law Revision Counsel’s text of 21 U.S.C. § 811 includes subsection (h), which authorizes an emergency order when the statutory conditions are met. It also provides for advance notice before an order may issue. That notice-and-order sequence explains why the reader needs both documents. The October notice identifies the proposal and the agency’s reasoning; an eventual order would supply the enacted regulatory text and its effective date. The linked edition states that it includes federal laws in effect through October 9, 2026. Check for later enacted changes when applying the provision to a later event.
The October notice also says the DEA withdrew its earlier July notice concerning a different proposed threshold. A screenshot of the July announcement may therefore give a reader the wrong proposed concentration. The Department of Justice’s October 2026 announcement describes the update, but the Federal Register documents are the better place to check the legal text. Save the relevant document number, publication date, status, and effective-date provision rather than relying on the date a social post was shared.
For example, a retailer checking a shelf on a Monday and a person examining a transaction from an earlier Friday may need different editions of the federal schedule. Record the date of the conduct and the date shown on the source. Then look for a superseding order, a withdrawal, or a later effective date. A current web page is useful for identifying today’s rule; it does not automatically establish what the rule said on every earlier date.
The October notice also cautions that neither the Department of Health and Human Services nor the DEA made a finding that products below the proposed threshold are safe. The Food and Drug Administration’s 7-OH information page discusses its own public-health concerns. FDA information is agency guidance and reporting; it is not a substitute for identifying the applicable scheduling order or a product-specific legal determination.
B. What do the proposed thresholds mean for an actual package?
The October federal notice describes two alternative threshold tests. First, it refers to a concentration greater than one milligram of 7-OH or mitragynine pseudoindoxyl per gram of a solid preparation, or greater than one milligram per milliliter of a liquid preparation. If both substances are present, the notice uses their combined amount. Second, it describes a ratio test: the mass of mitragynine divided by the mass of the specified substance or combined substances is less than 100. These are the notice’s proposed terms, not a shortcut for deciding the outcome under a later order.
The two tests ask different questions. Concentration compares the relevant amount with the weight or volume of the preparation. The ratio compares the amount of mitragynine with the amount of 7-OH, mitragynine pseudoindoxyl, or both. A label that lists only a total amount per serving may leave out the denominator needed for either calculation. A package may also omit one of the compounds relevant to the comparison. Do not assume that the same number can answer both tests.
Suppose a hypothetical solid product is reported to contain two milligrams of 7-OH in two grams of preparation. That arithmetic is one milligram per gram, not greater than one milligram per gram. But the proposed ratio test and any additional relevant substance would still need their own assessment, and a final order could use different wording. The example illustrates a calculation only; it does not decide whether any real item complies with federal or state law.
For a separate hypothetical ratio calculation, suppose a tested preparation contains 200 milligrams of mitragynine and two milligrams of 7-OH, with no mitragynine pseudoindoxyl detected in the sample. Dividing 200 by two gives a ratio of 100. The October proposal describes a ratio of less than 100, so this hypothetical figure alone would not meet that particular test. The concentration test would still require the weight or volume of the entire preparation, and a test result would need to be evaluated for the actual sample and its limits. A ratio from a label is not a substitute for the operative text or reliable measurement.
Likewise, a claim that a product comes from a plant does not establish the amount or legal classification of every ingredient in the finished preparation. The notice describes a threshold designed in part around products with levels closer to those found in the plant. The applicable legal inquiry still turns on the actual regulatory language and the preparation at issue. A product’s name, the retailer’s description, and an ingredient list can be starting points, but they are not laboratory findings.
Keep the packaging, the lot or batch number, a dated purchase record, a full ingredient panel, and any certificate of analysis provided with the specific batch. If there is a lab report, note what sample was tested, what compounds were measured, the units used, and whether the report reports a per-serving amount, a weight concentration, or a liquid concentration. A report for a different batch or a general marketing page may not answer the question about the item in hand.
Do not turn an unavailable test result into an assumption. If a report measures 7-OH but not mitragynine pseudoindoxyl, it may not answer a question about combined amounts. If it measures a raw ingredient rather than the finished preparation, the denominator may differ from the one used in the proposed rule. A retailer deciding what to do with a product should compare the actual source data with the text that applies on the date of the contemplated transaction.
The FDA’s warning also gives a separate practical reason to distinguish legal status from product safety. A threshold in a future controlled-substance order would define the scope of that order; it would not be a federal finding that consuming every product below the threshold is safe. Nor would a question about controlled-substance scheduling answer every issue under federal food and drug rules or a particular state’s law. Check the rule concerned before treating one agency’s announcement as an answer to all of them.
If an order is published after the notice, read its operative language, not only its heading. Check the substances, mixtures and exceptions it actually covers, the effective date, and what it says about the August order. If the new text differs from the notice, apply the issued text to the period it governs. Until then, characterize the threshold as proposed and keep the existing controls for the separately scheduled substances in view.
II. Can a product raise a separate federal analogue question?
A. What have courts decided about proof and knowledge?
Under federal law, a substance does not become a controlled substance analogue merely because a headline calls it similar to another drug. 21 U.S.C. § 813 provides for a controlled substance analogue to be treated as Schedule I to the extent intended for human consumption. Its text lists factors that may be considered when determining that intended use, including marketing and labeling, while saying that a label against human consumption alone is not enough to establish the opposite. The linked Office of the Law Revision Counsel edition states that it includes laws in effect through October 9, 2026.
The separate federal definition appears in 21 U.S.C. § 802(32). It addresses chemical structure, effects on the central nervous system, and, in a provision concerning a particular person, representations or intended effects. The section also lists exclusions, including a substance that is already a controlled substance and certain substances with approved or investigational drug status. Whether a particular exclusion or criterion applies requires the precise substance and facts; the statutory list is not a finding about this product or a substitute for a court’s interpretation.
That distinction is practical when a document mentions more than one compound. A batch record may report the principal ingredient but omit an impurity or a second compound. A laboratory analysis may use a detection limit that affects what a result can show. Check whether the reported substance is the one actually named in a schedule or the one addressed by the legal theory being asserted. If the evidence is incomplete, describe the missing measurement instead of assigning the entire mixture a legal status based on its brand name or plant source.
On June 18, 2015, the Supreme Court of the United States decided McFadden v. United States, 576 U.S. 186 (2015). The Court vacated the appellate judgment because the jury instruction had not conveyed the required knowledge in a federal prosecution under 21 U.S.C. § 841(a)(1) involving an analogue. It explained that the government could establish the required knowledge through knowledge that the substance was controlled, or through knowledge of the features making it an analogue. For a reader assessing a federal allegation, the substance’s classification and the evidence of the person’s knowledge are separate questions, and both must be examined.
The decision did not determine the chemical identity or legal status of 7-OH. It addressed substances involved in the case before the Court and the knowledge instruction given to the jury. The Court also said that evidence can be circumstantial. That is why an invoice, packaging, communications, testing, and the circumstances of a transaction can matter in a particular dispute without any one document automatically deciding it.
In Peña Garcia v. Department of Labor, No. 23-8066 (2d Cir. Mar. 5, 2026), the United States Court of Appeals for the Second Circuit, on March 5, 2026, cited McFadden’s description of the federal prohibition on knowing distribution while deciding a separate workers’ compensation issue concerning marijuana. That later citation addresses the general federal controlled-substance framework; it did not decide a 7-OH analogue question. It is a useful reminder to read what a later court actually used a case for rather than treating every citation as a ruling on the same product.
On December 27, 2023, the United States Court of Appeals for the Ninth Circuit decided United States v. Galecki, 89 F.4th 713 (9th Cir. 2023). The court upheld the analogue-related drug-trafficking convictions after reviewing the evidence of knowledge in that case and rejected an as-applied vagueness challenge. The evidence involved synthetic cannabinoid products, not 7-OH. The practical application is to examine the actual substance, evidence, and charge instead of importing the result of a different product’s prosecution.
The United States Court of Appeals For the Seventh Circuit later cited Galecki in United States v. Williams, 106 F.4th 639 (7th Cir. 2024), No. 22-3179 (7th Cir. Jul. 2, 2024), decided July 2, 2024. Williams referred to Galecki in discussing a vagueness challenge and the use of scientific similarity; it did not rule that 7-OH is an analogue. The Ninth and Seventh Circuit decisions are distinct appellate decisions, and their geographic reach and the questions each decided must be kept in view.
On July 2, 2024, the United States Court of Appeals For the Seventh Circuit decided United States v. Williams, 106 F.4th 639 (7th Cir. 2024). The court held that the phrase “analogue of fentanyl” in the particular federal sentencing provision before it was different from the statutory term “controlled substance analogue” and rejected the vagueness challenge as applied to furanyl fentanyl. For a reader, the application is to identify the exact statutory phrase and provision before carrying a definition from one federal context into another.
On August 21, 2026, the United States District Court for the Western District of Wisconsin cited Williams in United States v. Roberson, No. 25-cr-133-jdp (W.D. Wis. Aug. 21, 2026), for the fair-notice principle in an as-applied vagueness discussion in a firearm case. That later use concerned a different statute and does not decide how the analogue definition applies to 7-OH. A later citation is evidence of a particular use of a decision, not a complete check of every subsequent legal development.
These cases illustrate why a package cannot be classified by syllogism: a product may have a familiar name, contain more than one compound, or be discussed in an agency notice, but the legal questions still depend on the text, the substance, and the relevant evidence. A court’s decision about another compound can help explain a method of analysis without resolving the outcome for this product.
B. What should a reader preserve and compare?
Separate three questions on paper. First, which federal scheduling document was in force on the relevant date? Second, what does reliable evidence show was in the particular item? Third, is someone asserting a different federal theory, such as treatment as a controlled substance analogue, or a separate state-law violation? A “yes” or “no” on the first question does not by itself answer the other two.
For the first question, preserve the notice or order’s title, document number, dates, and operative text. The October 2026 notice is useful because it expressly distinguishes a proposed threshold for 7-OH and mitragynine pseudoindoxyl from the August order already covering the latter without that threshold. If a later order exists at the time of a transaction, save it too, together with any document withdrawing the earlier rule. Avoid relying on an undated excerpt that could combine the proposed and existing rules.
For the second question, preserve what identifies the actual preparation. A photograph of the package can show the label and batch number; a receipt can help place the transaction in time; a manufacturer’s batch-specific report may show which compounds a laboratory measured. Keep the complete report and its stated units. Where the package and report differ, note the discrepancy instead of selecting whichever figure produces a preferred answer.
For the third question, read the specific notice, charge, seizure paperwork, or other document involved. It may name a compound or a statutory provision that differs from the shorthand used on the product label. The presence of the word “analogue” in a discussion does not settle which legal definition is being used. Williams shows why the text of the exact provision is important; McFadden shows why the required knowledge in a charged federal distribution offense also matters.
A person responding to a federal inquiry should keep original records intact and distinguish what is known personally from what came from a label or another person. A retailer can organize supplier correspondence, invoices, batch documents, and sales records by date and product rather than blending information from different items. An unexplained gap in those records is a gap to investigate, not proof that a specific chemical was present or absent.
The same discipline applies to online explanations. An article published before the October notice may accurately describe a former proposal while no longer describing the agency’s latest position. A page published after the notice may predict an order without showing that the order was actually issued. Compare the official document’s status and effective date with the claim made in the page. If a claim describes a state ban, identify the state and the state’s actual rule rather than treating the statement as a federal result.
Federal and state rules can coexist. This article’s analysis is federal; it does not decide whether a particular state has restricted a product, what a local agency may require, or whether a given label satisfies food and drug requirements. A person checking a real product should identify the state and the type of activity—such as possession, sale, distribution, or labeling—before looking for the relevant state text. A change to one federal schedule does not automatically answer those distinct questions.
Finally, keep the limits of the evidence visible. The October notice describes the DEA’s intended action, and the August order addresses three separately named substances. The cases explain rules and outcomes in their own records. None of those sources identifies the ingredients of an untested package in your possession. A careful decision begins with the document and the product that actually match the question.
Conclusion
The federal notice set an earliest point for a proposed temporary 7-OH order; it did not make the calendar date itself the order. Check the latest issued text and its effective date, distinguish the existing schedule entry for mitragynine pseudoindoxyl and the other named compounds, and compare the rule with reliable information about the particular preparation. Any separate analogue or state-law question requires its own legal text and evidence.